Interleukin-3 Polymorphism is Associated with Miscarriage of Fresh in Vitro Fertilization Cycles
by
, , , ,
Cheng-Hsuan Wu
1,2,3
,
Tsung-Hsien Lee
1,4,*,†
,
Shun-Fa Yang
1,5
,
Hui-Mei Tsao
6,
Yu-Jun Chang
7,
Chia-Hsuan Chou
1,5 and
Maw-Sheng Lee
1,4,6,*,† 1
Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan
2
Women’s Health Research Laboratory, Changhua Christian Hospital, Changhua 50006, Taiwan
3
School of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
4
Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
5
Department of Medical Research, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
6
Division of Infertility Clinic, Lee Womens’ Hospital, Taichung 406, Taiwan
7
Epidemiology and Biostatistics Center, Changhua Christian Hospital, Changhua 50006, Taiwan
*
Authors to whom correspondence should be addressed.
†
These two authors contributed equally to this work.
Int. J. Environ. Res. Public Health 2019, 16(6), 995; https://doi.org/10.3390/ijerph16060995
Submission received: 3 February 2019
/
Revised: 5 March 2019
/
Accepted: 17 March 2019
/
Published: 19 March 2019
(This article belongs to the Special Issue Big Data, Decision Models, and Public Health)
Abstract
:The aim of this study was to examine the association between interleukin (IL) genes polymorphisms and in vitro fertilization (IVF) outcome. A prospective cohort analysis was performed at a Women’s Hospital IVF centre of 1015 female patients undergoing fresh non-donor IVF cycles. The effects of the following six single nucleotide polymorphisms (SNPs) in five IL genes on IVF outcomes were explored: IL-1α (rs1800587 C/T), IL-3 (rs40401 C/T), IL-6 (rs1800795 C/G), IL-15 (rs3806798 A/T), IL-18 (rs187238 C/G) and IL-18 (rs1946518 G/T). The main outcome measures included clinical pregnancy, embryo implantation, abortion and live birth rates. There were no statistically significant differences in clinical pregnancy, embryo implantation and live birth rates in the analysis of 1015 patients attempting their first cycle of IVF. Infertile women with IL-3 homozygous major genotype had a higher abortion rate than those with heterozygous and homozygous minor genotype (16.5% vs. 7.9%, P = 0.025). In conclusion, our results indicated that the IL-3 rs40401 polymorphism is associated with increased risk of abortion of IVF patients. Future studies with inclusion of other ethnic populations must be conducted to confirm the findings of this study.
1. Introduction
Despite numerous technical advances in the administration of in vitro fertilization (IVF) to infertile couples, embryo implantation remains the rate-limiting step for a successful IVF procedure [1]. The endometrium is receptive to the embryo only during a period known as the implantation window. During this period, both the developing embryo and the receptive endometrium undergo a synchronized complex process involving several factors including immune cells, growth factors, cytokines and adhesion molecules [2,3]. It is believed that the events underlying the endometrial receptivity are products of several genes; therefore, alterations due to polymorphisms in genes involved in embryo implantation could lead to IVF failure [4,5].
Among the large number of embryo implantation failure or miscarriage-related factors, interleukins those involved in abnormal immune reactions are particularly notable [6]. Interleukins are a group of immunomodulatory proteins that mediate several immune reactions in human body. The interleukin (IL)-1 system is composed of a family of peptides, including two agonists, IL-1α and IL-1β. IL-1α may have a critical function in the development of obesity [7]. Increasing body weight is associated with significantly lower progesterone concentrations in early pregnancy after blastocyst transfer and affects the IVF outcome [8]. IL-3 is a haematopoiesis promoting factor and aids in embryo implantation and placental development, whose maternal serum level increases as a function of the trimester [9]. IL-3 gene polymorphisms were associated with acute rejection after kidney transplantation [10]. IL-6 plays a role in reproduction and immune balance, acting as a multifunctional cytokine with anti- and pro-inflammatory response and regulates the behaviour of the gestational tissues [11]. Liu et al. demonstrated a possible association between IL-6-174 promoter polymorphism and recurrent spontaneous abortion [12]. IL-15 is implicated in the recruitment and proliferation of uterine natural killer (NK) cells in the endometrium [13]. Increased expression of IL-15 in the placenta tissue of patients may be connected to disturbed implantation with following foetal loss [14]. IL-18, mainly produced by macrophages, stimulates IFN-γ production and activates NK and T cells, which are involved in uterine implantation [15]. Serum IL-18 level is associated with response to ovarian stimulation and plays an important role in a successful pregnancy outcome after IVF treatment [16].
Studies have illustrated that genetic variations in IL genes responsible for regulating the activity of the immune system might cause embryo implantation failure or early pregnancy loss [17]. After meta-analysis, a systematic review indicated that a significant association between IL-1β (-511C/T) polymorphism and recurrent miscarriage (RM) [18]. Likewise, research conducted in Iranian women has revealed a relationship between the IL-6 rs1800796 (−634C/G) polymorphism and an increased risk of RM [19]. In addition, Yue et al. showed that the IL-18-137G/C gene polymorphism may contribute to pathogenesis of idiopathic RM in Chinese Han population. Al-Khateeb et al. reported that two SNPs of IL-18 (rs360717 and rs1946519) are significantly associated with RM [15]. Finally, the effects of IL-3 and IL-15 polymorphisms on pregnancy outcomes have not been studied yet. It must be highlighted that none of the above studies were conducted in an IVF population. Therefore, we decided to assess the possible correlations between the IL polymorphisms and pregnancy outcomes based on IVF population. Our findings would be of value as a prognostic indicator of successful IVF outcomes.
2. Materials and Methods
2.1. Study Design and Subjects
Women undergoing IVF at the Lee Women’s Hospital in Taichung, Taiwan (n = 1015) were prospectively enrolled in the study from January 2014 to December 2015. The causes of infertility included male factor, tubal factor, endometriosis, polycystic ovarian syndrome (PCOS), advance maternal age, unexplained and others. Eligibility inclusion criteria were: (1) a woman age ≤ 40 years old; (2) undergoing the first IVF or intracytoplasmic sperm injection (ICSI) cycle; and (3) blastocyst transfer in the fresh cycle. Exclusion criteria were autoimmune dysfunction, genetic anomalies, inflammatory disease and other systemic disorders. A venous blood sample was drawn for DNA extraction with subsequent interleukin genotyping. Ethics approval (CS13194) was obtained from the Institutional Review Board of Chung Shan Medical University Hospital.
We studied the effects of the following six single-nucleotide polymorphisms (SNPs) in five IL genes on IVF outcomes: IL-1α C/T rs1800587 (C___9546481_20), IL-3 C/T rs40401 (C___2397269_30), IL-6 C/G rs1800795 (C___1839697_20), IL-15 A/T rs3806798 (C__27519194_10), IL-18 C/G rs187238 (C___2408543_10) and IL-18 G/T rs1946518 (C___2898460_10). The details of the selected SNP were described in supplementary Table S1. Relevant IVF outcomes were clinical pregnancy, embryo implantation, abortion and live birth. Clinical pregnancy was defined as the presence of an intrauterine gestational sac (GS). Embryo implantation rate was calculated by dividing the number of implanted GS by the number of embryos transferred. Spontaneous abortion is defined as the natural loss of a pregnancy with an ultrasound-confirmed GS before 20 gestational weeks. Live birth was considered birth after 24 weeks of gestation.
2.2. IVF Treatment Protocol
The details of a stimulation cycle procedure have been previously described [20]. Patients underwent either a standard long protocol using the gonadotrophin-releasing hormone (GnRH) agonist or a short protocol using GnRH antagonists. The long protocol began with daily subcutaneous injections of 0.5 mg of leuprolide acetate (Lupron; Takeda Pharmaceutics, Konstantz, Germany) from cycle Day 21 of the previous cycle. On cycle day 3, recombinant FSH (Gonal-F, Merck-Serono, Darmstadt, Germany) or highly purified FSH (Menopur; Ferring Pharmaceuticals, Kiel, Germany) was administered via individual set with flexible doses. Patients on the antagonist protocol had gonadotrophin stimulation initiated on day 3 of the cycle and the GnRH antagonist (Orgalutran; Organon Laboratories) at a daily dose of 0.25 mg was administered using a fixed day 6 protocol. Final oocyte maturation was triggered with 10,000 IU human Chorionic Gonadotropin (Profasi; Serono) and oocyte retrieval was performed 36 to 38 hours later. Fertilization was carried out either by conventional insemination or ICSI depending on the semen parameters. Fresh blastocyst transfer was performed throughout the study period.
2.3. DNA Extraction and Determination of Genotypes
Genomic DNA was extracted from EDTA anti-coagulated venous blood using a QIAamp DNA blood mini kit (Qiagen, Valencia, USA), according to the manufacturer’s instructions described in detail previously [21]. DNA was dissolved in TE buffer (10 mM Tris and 1 mM EDTA acid; pH 7.8) and then quantitated by a measurement of the optical density at 260 nm. The final preparation was stored at −20 °C and used as templates for polymerase chain reaction (PCR). Allelic discrimination of the six studied SNPs was assessed with the ABI StepOne™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and analysed using SDS vers. 3.0 software (Applied Biosystems, Foster City, CA, USA), with the TaqMan assay [22].
2.4. Statistical Analysis
The demographic data and other clinically relevant data of continuous variables are presented as mean and standard deviation, whereas categorical variables were presented as percentage. The chi-square test was used to investigate the different effects of IL polymorphisms on IVF outcome. Continuous variables between the 2 groups were compared using the Student’s t-test. All data were analysed using the IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY). p-values < 0.05 were considered statistically significant.
3. Results
There were 1015 patients attempting their first fresh cycle of IVF. The genotypic frequencies of IL SNPs are shown in Table 1. Genotypic distributions of IL-1α (rs1800587 C/T), IL-3 (rs40401 C/T), IL-18 (rs187238 C/G) and IL-18 (rs1946518 G/T) conformed to Hardy-Weinberg equilibrium (p = 0.469, χ2 value: 0.525; p = 0.486, χ2 value: 0.528; p = 0.330, χ2 value: 0.950 and p = 0.873, χ2 value: 0.025; respectively), except for IL-15 (rs3806798 A/T) (p = 0.030, χ2 value: 4.723). The following notation will be used for describing the genotypes of all SNPs: homozygous major as “AA,” heterozygous as “Aa” and homozygous minor as “aa.” The genotypes frequencies of IL-6 polymorphism were AA (100%), Aa (0%) and aa (0%). Table 2 outlines the baseline and IVF treatment cycle characteristics of 1015 IVF patients.
Table 3 shows the association between IL polymorphisms and IVF outcomes. There were no statistically significant differences found in clinical pregnancy, embryo implantation, abortion or live birth rates. We did not examine the association between IL-6 polymorphism and IVF outcomes because of the 100% frequency of the homozygous major genotype. Combining the genotypes with the minor allele (Aa/aa) and comparing them to the homozygous major genotype (AA) yielded statistically insignificant results for clinical pregnancy, embryo implantation or live birth rates. However, a statistically significant difference in abortion rate was found for the recessive model of IL-3 SNP (16.5% for AA and 7.9% for Aa/aa, p = 0.025) (Table 4).
The baseline and IVF treatment cycle characteristics of IL-3 polymorphism patients were shown in Table 5. The baseline characteristics of the both subgroups (AA and Aa/aa), especially age, ovarian reserve indexes and infertility duration, were not statistically different. Also, no significant differences were observed in the factors thought to affect the outcome measures during IVF treatment, including the number of mature oocytes, fertilization rates, Day 5 good embryo rate, number of transferred embryos and endometrial thickness.
4. Discussion
Throughout its 40-year history, IVF has improved significantly. However, implantation and pregnancy rates with IVF have increased slowly year after year [23]. Therefore, a more specific recognition of patients’ individual genetic profiles may be helpful in the appraisal of each woman’s intrinsic capacity to become pregnant. In this study, the maternal genetic profile at six gene polymorphisms associated with immune and inflammation were investigated in a cohort of IVF patients and IL-3 was shown to be associated with IVF abortion. To the best of our knowledge, our study is the first to report that the IL-3 genetic polymorphism can affect abortion rates in Taiwan Han IVF population.
It must be emphasized that only one study was done to investigate the relationships between the IL polymorphisms and IVF outcomes and found that IL-1 receptor antagonist gene polymorphism is associated with a poor prognosis of obtaining a pregnancy after IVF [24]. In our study, we found no association between IL-1α, IL-15 or IL-18 SNPs and IVF outcomes. However, a meta-analysis showed that the IL-18 polymorphism is associated with an increased risk of recurrent pregnancy loss [18]. A possible explanation for this discrepancy is that our study was conducted in an IVF population, whereas the populations pooled for the meta-analysis were not IVF subjects.
This study revealed that IL-3 rs40401 C/T polymorphisms had higher abortion rate in IVF patients. Spontaneous miscarriage is the most common complication of pregnancy and occurs in 10–15% of pregnancies during the first trimester [25]. The mechanisms of pregnancy loss are not completely understood. It is believed that apart from chromosomal, embryonic and anatomical defects, immunologic rejection of the embryo by the maternal immune system may be involved [26].
To maintain a healthy pregnancy, human endometrial endothelial cells (HEECs) produce a number of chemokines and proangiogenic factors that may promote immune cell recruitment, trophoblast invasion and spiral artery remodelling, which establishes the adequate placentation and vascular development [27]. Women with antiphospholipid antibodies (aPL) are at risk for pregnancy loss [28]. Previous in vitro studies have revealed that aPL inhibits HEEC vascular endothelial growth factor secretion and their ability to form vessel-like structures [29,30]. A systemic review also showed that aPL can directly affect trophoblast function and lead to impaired placentation and vascular transformation [31].
Women with pregnancy loss due to the anti-phospholipid antibody syndrome (APS) have reduced levels of IL-3 [32]. IL-3 belongs to the family of hematopoietic cytokines [33] and is a growth factor for the trophoblast that assists in embryo implantation and placental development [34]. Mice with aPL-induced foetal loss have low levels of IL-3 and administration of recombinant IL-3 to the affected mice increased pregnancy success [35]. The mechanism by which IL-3 reverses the effects of aPL on pregnancy is not completely understood. Di Simone et al. [36] submitted that IL-3 can reverse the effects of aPL on hormone secretion and trophoblast invasion. However, Chamley et al. question if it has the same effects on human trophoblasts [37]. Savion et al. showed the ability of ciprofloxacin to reduce pregnancy loss in the mouse model, possibly through elevation of IL-3 [38].
Furthermore, IL-3 is the main cytokine for the generation of dendritic cells (DCs), which play a role in inducing T helper 2 (Th2) cell responses [39]. IL-3-treated monocyte-derived DC shifts Th cell responses toward a Th2 cytokine pattern [39]. Thus, the activity of IL-3 may influence the balance between Th1 and Th2 cytokines. Imbalance in Th1/Th2 cytokine level is a critical factor associated with foetus abortion. Th1 type response has been related to pregnancy failure, whereas the Th2 type dominant response has been associated with normal pregnancy [40]. Significantly elevated level of Th1/Th2 cytokine is present in infertile women with multiple implantation failures after IVF and in women with recurrent pregnancy losses [41].
Maternal age has great impact on IVF pregnancy outcome. The association of IL SNPs with pregnancy outcome was further analysed by stratification with age of 35 in Table 3 and Table 4. We found that the impact of IL-3 SNP on abortion is borderline significantly for young age patients, which suggest that the effect of IL-3 SNP on abortion is not associated with advanced maternal age.
This study has multiple strengths. First, it used a large prospective sample size, which decreases the risk for selection bias. Second, this study included all patients undergoing their first fresh IVF cycle and consented to DNA use. Including patients who failed multiple cycles will obscure any effects of the SNPs because other factors, such as poor oocyte quality, are more likely to significantly influence the IVF outcomes. Third, we collected live birth data, which is ultimately the outcome of interest to the patient.
5. Conclusions
In summary, our results indicated that IL-3 variant is associated with increased risk of abortion of IVF patients. The limitation of the study was performed only in an IVF population of Taiwan Han ethnicity. Future more large-scale population studies with inclusion of other ethnic backgrounds must be conducted to confirm that IL-3 variant rs40401 is associated with IVF abortion. The mechanism underlying the role of IL-3 in abortion remains to be determined. To define the role of IL-3, comprehensive functional experiments are also needed.
Supplementary Materials
The following are available online at https://www.mdpi.com/1660-4601/16/6/995/s1, Table S1: Description of selected single-nucleotide polymorphism (SNP).
Author Contributions
Conceptualization, C.-H.W., S.-F.Y., T.-H.L. and M.-S.L.; Validation, C.-H.W. and M.-S.L.; Formal Analysis, H.-M.T., C.-H.C. and Y.-J.C.; Writing-Original Draft Preparation, C.-H.W., T.-H.L. and M.-S.L.; Writing-Review & Editing, C.-H.W., T.-H.L. and M.-S.L.
Funding
This research received no external funding.
Acknowledgments
This study was supported by 105-CCH-IRP-046 from Changhua Christian Hospital, Taiwan.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Peter Durairaj, R.R.; Aberkane, A.; Polanski, L.; Maruyama, Y.; Baumgarten, M.; Lucas, E.S.; Quenby, S.; Chan, J.K.Y.; Raine-Fenning, N.; Brosens, J.J.; et al. Deregulation of the endometrial stromal cell secretome precedes embryo implantation failure. Mol. Hum. Reprod. 2017, 23, 478–487. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van Mourik, M.S.; Macklon, N.S.; Heijnen, C.J. Embryonic implantation: Cytokines, adhesion molecules, and immune cells in establishing an implantation environment. J. Leukoc. Biol. 2009, 85, 4–19. [Google Scholar] [CrossRef]
- Dekel, N.; Gnainsky, Y.; Granot, I.; Racicot, K.; Mor, G. The role of inflammation for a successful implantation. Am. J. Reprod. Immunol. 2014, 72, 141–147. [Google Scholar] [CrossRef] [PubMed]
- Ivanov, A.V.; Dedul, A.G.; Fedotov, Y.N.; Komlichenko, E.V. Toward optimal set of single nucleotide polymorphism investigation before IVF. Gynecol. Endocrinol. 2016, 32, 11–18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pathare, A.D.S.; Zaveri, K.; Hinduja, I. Downregulation of genes related to immune and inflammatory response in IVF implantation failure cases under controlled ovarian stimulation. Am. J. Reprod. Immunol. 2017, 78, e12679. [Google Scholar] [CrossRef]
- Choi, Y.K.; Kwak-Kim, J. Cytokine gene polymorphisms in recurrent spontaneous abortions: A comprehensive review. Am. J. Reprod. Immunol. 2008, 60, 91–110. [Google Scholar] [CrossRef] [PubMed]
- Um, J.Y.; Rim, H.K.; Kim, S.J.; Kim, H.L.; Hong, S.H. Functional polymorphism of IL-1 alpha and its potential role in obesity in humans and mice. PLoS ONE 2011, 6, e29524. [Google Scholar] [CrossRef]
- Mejia, R.B.; Cox, T.W.; Nguyen, E.B.; Summers, K.M.; Eyck, P.T.; Sparks, A.E.; Van Voorhis, B.J. Effect of body weight on early hormone levels in singleton pregnancies resulting in delivery after in vitro fertilization. Fertil. Steril. 2018, 110, 1311–1317. [Google Scholar] [CrossRef]
- Holtan, S.G.; Chen, Y.; Kaimal, R.; Creedon, D.J.; Enninga, E.A.; Nevala, W.K.; Markovic, S.N. Growth modeling of the maternal cytokine milieu throughout normal pregnancy: Macrophage-derived chemokine decreases as inflammation/counterregulation increases. J. Immunol. Res. 2015, 2015, 952571. [Google Scholar] [CrossRef]
- Lee, D.Y.; Song, S.B.; Moon, J.Y.; Jeong, K.H.; Park, S.J.; Kim, H.J.; Kang, S.W.; Lee, S.H.; Kim, Y.H.; Chung, J.H.; et al. Association between interleukin-3 gene polymorphism and acute rejection after kidney transplantation. Transplant. Proc. 2010, 42, 4501–4504. [Google Scholar] [CrossRef]
- Drozdzik, M.; Szlarb, N.; Kurzawski, M. Interleukin-6 level and gene polymorphism in spontaneous miscarriage. Tissue Antigens 2013, 82, 171–176. [Google Scholar] [CrossRef] [PubMed]
- Liu, R.X.; Wang, Y.; Wen, L.H. Relationship between cytokine gene polymorphisms and recurrent spontaneous abortion. Int. J. Clin. Exp. Med. 2015, 8, 9786–9792. [Google Scholar] [PubMed]
- Mariee, N.; Li, T.C.; Laird, S.M. Expression of leukaemia inhibitory factor and interleukin 15 in endometrium of women with recurrent implantation failure after IVF; correlation with the number of endometrial natural killer cells. Hum. Reprod. (Oxf. Engl.) 2012, 27, 1946–1954. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Toth, B.; Haufe, T.; Scholz, C.; Kuhn, C.; Friese, K.; Karamouti, M.; Makrigiannakis, A.; Jeschke, U. Placental interleukin-15 expression in recurrent miscarriage. Am. J. Reprod. Immunol. 2010, 64, 402–410. [Google Scholar] [CrossRef] [PubMed]
- Al-Khateeb, G.M.; Sater, M.S.; Finan, R.R.; Mustafa, F.E.; Al-Busaidi, A.S.; Al-Sulaiti, M.A.; Almawi, W.Y. Analysis of interleukin-18 promoter polymorphisms and changes in interleukin-18 serum levels underscores the involvement of interleukin-18 in recurrent spontaneous miscarriage. Fertil. Steril. 2011, 96, 921–926. [Google Scholar] [CrossRef] [PubMed]
- Gunther, V.; Alkatout, I.; Fuhs, C.; Salmassi, A.; Mettler, L.; Hedderich, J.; Maass, N.; Elessawy, M.; Schmutzler, A.G.; Eckmann-Scholz, C. The Role of Interleukin-18 in Serum and Follicular Fluid during In Vitro Fertilization and Intracytoplasmic Sperm Injection. BioMed Res. Int. 2016, 2016, 6379850. [Google Scholar] [CrossRef] [PubMed]
- Daher, S.; Mattar, R.; Gueuvoghlanian-Silva, B.Y.; Torloni, M.R. Genetic polymorphisms and recurrent spontaneous abortions: An overview of current knowledge. Am. J. Reprod. Immunol. 2012, 67, 341–347. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M.; Xu, J.; Bao, X.; Niu, W.; Wang, L.; Du, L.; Zhang, N.; Sun, Y. Association between Genetic Polymorphisms in Interleukin Genes and Recurrent Pregnancy Loss—A Systematic Review and Meta-Analysis. PLoS ONE 2017, 12, e0169891. [Google Scholar] [CrossRef]
- Nasiri, M.; Rasti, Z. CTLA-4 and IL-6 gene polymorphisms: Risk factors for recurrent pregnancy loss. Hum. Immunol. 2016, 77, 1271–1274. [Google Scholar] [CrossRef]
- Wu, C.H.; Lee, T.H.; Chen, H.H.; Chen, C.I.; Huang, C.C.; Lee, M.S. The influence of female age on the cumulative live-birth rate of fresh cycles and subsequent frozen cycles using vitrified blastocysts in hyper-responders. Taiwan J. Obs. Gynecol. 2015, 54, 567–571. [Google Scholar] [CrossRef] [Green Version]
- Chung, T.T.; Pan, M.S.; Kuo, C.L.; Wong, R.H.; Lin, C.W.; Chen, M.K.; Yang, S.F. Impact of RECK gene polymorphisms and environmental factors on oral cancer susceptibility and clinicopathologic characteristics in Taiwan. Carcinogenesis 2011, 32, 1063–1068. [Google Scholar] [CrossRef] [Green Version]
- Tsai, H.T.; Hsin, C.H.; Hsieh, Y.H.; Tang, C.H.; Yang, S.F.; Lin, C.W.; Chen, M.K. Impact of interleukin-18 polymorphisms -607A/C and -137G/C on oral cancer occurrence and clinical progression. PLoS ONE 2013, 8, e83572. [Google Scholar] [CrossRef]
- Society for Assisted Reproductive Technology. Clinic Summary Report. Available online: https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?ClinicPKID=0 (accessed on 25 April 2018).
- Gremlich, S.; Fratta, S.; Rebellato, E.; Uras, R.; Reymondin, D.; Damnon, F.; Germond, M.; Gerber, S. Interleukin-1 receptor antagonist gene (IL-1RN) polymorphism is a predictive factor of clinical pregnancy after IVF. Hum. Reprod. (Oxf. Engl.) 2008, 23, 1200–1206. [Google Scholar] [CrossRef] [Green Version]
- Viaggi, C.D.; Cavani, S.; Malacarne, M.; Floriddia, F.; Zerega, G.; Baldo, C.; Mogni, M.; Castagnetta, M.; Piombo, G.; Coviello, D.A.; et al. First-trimester euploid miscarriages analysed by array-CGH. J. Appl. Genet. 2013, 54, 353–359. [Google Scholar] [CrossRef]
- Comba, C.; Bastu, E.; Dural, O.; Yasa, C.; Keskin, G.; Ozsurmeli, M.; Buyru, F.; Serdaroglu, H. Role of inflammatory mediators in patients with recurrent pregnancy loss. Fertil. Steril. 2015, 104, 1467–1474. [Google Scholar] [CrossRef]
- Quao, Z.C.; Tong, M.; Bryce, E.; Guller, S.; Chamley, L.W.; Abrahams, V.M. Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies. Am. J. Reprod. Immunol. 2018, 79, e12785. [Google Scholar] [CrossRef]
- Carp, H.J.; Shoenfeld, Y. Anti-phospholipid antibodies and infertility. Clin. Rev. Allergy Immunol. 2007, 32, 159–161. [Google Scholar] [CrossRef]
- Di Simone, N.; Di Nicuolo, F.; D’Ippolito, S.; Castellani, R.; Tersigni, C.; Caruso, A.; Meroni, P.; Marana, R. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol. Reprod. 2010, 83, 212–219. [Google Scholar] [CrossRef]
- Di Simone, N.; D’Ippolito, S.; Marana, R.; Di Nicuolo, F.; Castellani, R.; Pierangeli, S.S.; Chen, P.; Tersigni, C.; Scambia, G.; Meroni, P.L. Antiphospholipid antibodies affect human endometrial angiogenesis: Protective effect of a synthetic peptide (TIFI) mimicking the phospholipid binding site of beta(2) glycoprotein I. Am. J. Reprod. Immunol. 2013, 70, 299–308. [Google Scholar] [CrossRef]
- Tong, M.; Viall, C.A.; Chamley, L.W. Antiphospholipid antibodies and the placenta: A systematic review of their in vitro effects and modulation by treatment. Hum. Reprod. Update 2015, 21, 97–118. [Google Scholar] [CrossRef]
- Shoenfeld, Y.; Sherer, Y.; Fishman, P. Interleukin-3 and pregnancy loss in antiphospholipid syndrome. Scand. J. Rheumatol. Suppl. 1998, 107, 19–22. [Google Scholar] [CrossRef]
- Broughton, S.E.; Dhagat, U.; Hercus, T.R.; Nero, T.L.; Grimbaldeston, M.A.; Bonder, C.S.; Lopez, A.F.; Parker, M.W. The GM-CSF/IL-3/IL-5 cytokine receptor family: From ligand recognition to initiation of signaling. Immunol. Rev. 2012, 250, 277–302. [Google Scholar] [CrossRef]
- Chaouat, G.; Dubanchet, S.; Ledée, N. Cytokines: Important for implantation? J. Assist. Reprod. Genet. 2007, 24, 491–505. [Google Scholar] [CrossRef] [Green Version]
- Fishman, P.; Falach-Vaknine, E.; Zigelman, R.; Bakimer, R.; Sredni, B.; Djaldetti, M.; Shoenfeld, Y. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J. Clin. Investig. 1993, 91, 1834–1837. [Google Scholar] [CrossRef]
- Di Simone, N.; Caliandro, D.; Castellani, R.; Ferrazzani, S.; Caruso, A. Interleukin-3 and human trophoblast: In vitro explanations for the effect of interleukin in patients with antiphospholipid antibody syndrome. Fertil. Steril. 2000, 73, 1194–1200. [Google Scholar] [CrossRef]
- Chamley, L.W.; Konarkowska, B.; Duncalf, A.M.; Mitchell, M.D.; Johnson, P.M. Is interleukin-3 important in antiphospholipid antibody-mediated pregnancy failure? Fertil. Steril. 2001, 76, 700–706. [Google Scholar] [CrossRef]
- Savion, S.; Blank, M.; Shepshelovich, J.; Fishman, P.; Shoenfeld, Y.; Toder, V. Ciprofloxacin affects pregnancy loss in CBA/JxDBA/2J mice possibly via elevation of interleukin-3 and granulocyte macrophage-colony stimulating factor production. Am. J. Reprod. Immunol. 2000, 44, 293–298. [Google Scholar] [CrossRef]
- Ebner, S.; Hofer, S.; Nguyen, V.A.; Furhapter, C.; Herold, M.; Fritsch, P.; Heufler, C.; Romani, N. A novel role for IL-3: Human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern. J. Immunol. 2002, 168, 6199–6207. [Google Scholar] [CrossRef]
- Saito, S.; Nakashima, A.; Shima, T.; Ito, M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am. J. Reprod. Immunol. 2010, 63, 601–610. [Google Scholar] [CrossRef]
- Kwak-Kim, J.Y.; Chung-Bang, H.S.; Ng, S.C.; Ntrivalas, E.I.; Mangubat, C.P.; Beaman, K.D.; Beer, A.E.; Gilman-Sachs, A. Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Hum. Reprod. (Oxf. Engl.) 2003, 18, 767–773. [Google Scholar] [CrossRef] [Green Version]
Table 1.
The frequencies of IL-1α, IL-3, IL-6, IL-15 and IL-18 polymorphisms in in vitro fertilization (IVF) women.
Table 1.
The frequencies of IL-1α, IL-3, IL-6, IL-15 and IL-18 polymorphisms in in vitro fertilization (IVF) women.
| Variable | AA | Aa | aa | A Allele | a Allele | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 1015 | N | % | N | % | N | % | N | % | N | % |
| IL-1α C/T | 884 | 87.1 | 128 | 12.6 | 3 | 0.3 | 1896 | 93.3 | 134 | 6.6 |
| IL-3 C/T | 253 | 24.9 | 519 | 51.1 | 243 | 23.9 | 1025 | 50.4 | 1005 | 49.5 |
| IL-6 C/G | 1015 | 100.0 | 0 | 0.0 | 0 | 0.0 | 2030 | 100 | 0 | 0 |
| IL-15 A/T | 739 | 72.8 | 264 | 26.0 | 12 | 1.2 | 1742 | 85.8 | 288 | 14.1 |
| IL-18 C/G | 748 | 73.7 | 251 | 24.7 | 16 | 1.6 | 1747 | 86 | 283 | 13.9 |
| IL-18 G/T | 257 | 25.3 | 510 | 50.2 | 248 | 24.4 | 1024 | 50.4 | 1006 | 49.5 |
AA: homozygous major, Aa: heterozygous, aa: homozygous minor.
Table 2.
Clinical characteristics of women undergoing IVF treatment.
| Number of Patients | 1015 |
|---|---|
| Mean patient age (years) | 35.5 ± 4.6 |
| Cause of infertility | |
| Male factor (%) | 208 (20.5%) |
| Tubal factor (%) | 196 (19.3%) |
| Endometriosis (%) | 73 (7.2%) |
| PCOS (%) | 97 (9.6%) |
| Unexplained (%) | 79 (7.8%) |
| Advance maternal age (%) | 273 (26.9%) |
| Multiple factors (%) | 89 (8.7%) |
| Total gonadotropins administered (IU) | 2921 ± 892 |
| Basal FSH (mIU/mL) | 7.1 ± 4.4 |
| Basal LH (mIU/mL) | 6.5 ± 0.3 |
| Basal AMH (mIU/mL) | 3.1 ± 0.1 |
| Basal estradiol (pg/mL) | 52.3 ± 2.5 |
| Peak estradiol (pg/mL) * | 1892 ± 1342 |
| No. of oocytes retrieved | 10 ± 6.6 |
| No. of blastocyst stage embryos | 4.8 ±2.4 |
| No. of embryos transferred | 2.5 ± 0.9 |
| Fertilization rate (%) | 82.6 ± 21.1 |
| Endometrial thickness (mm) ** | 11.8 ± 2.1 |
Values presented as mean ± standard deviation. * levels on the trigger day, ** thickness on the day of embryo transfer.
Table 3.
Effect of Interleukin polymorphisms on IVF outcome.
| Variable | Age≤35 | Age>35 | Overall | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AA | Aa | aa | p-Value | AA | Aa | aa | p-Value | AA | Aa | aa | p-Value | ||
| Clinical pregnancy | |||||||||||||
| IL-1α | N | 180/444 | 28/64 | 2/2 | 0.242 | 100/440 | 15/64 | 0/1 | 0.903 | 280/884 | 43/128 | 2/3 | 0.358 |
| % | 40.5 | 43.8 | 100.0 | 22.7 | 23.4 | 0.0 | 31.7 | 33.6 | 66.7 | ||||
| OR | 1.000 | 1.141 | - | 1.000 | 1.041 | 0.000 | 1.000 | 1.091 | 4.314 | ||||
| IL-3 | N | 55/117 | 94/250 | 61/143 | 0.213 | 30/136 | 61/269 | 24/100 | 0.939 | 85/253 | 155/519 | 85/243 | 0.305 |
| % | 47.0 | 37.6 | 42.7 | 22.1 | 22.7 | 24.0 | 33.6 | 29.9 | 35.0 | ||||
| OR | 1.000 | 0.679 | 0.839 | 1.000 | 1.036 | 1.116 | 1.000 | 0.842 | 1.063 | ||||
| IL-15 | N | 154/378 | 56/130 | 0/2 | 0.550 | 78/361 | 35/134 | 2/10 | 0.555 | 232/739 | 91/264 | 2/12 | 0.340 |
| % | 40.7 | 43.1 | 0.0 | 21.6 | 26.1 | 20.0 | 31.4 | 34.5 | 16.7 | ||||
| OR | 1.000 | 1.101 | 0.000 | 1.000 | 1.283 | 0.907 | 1.000 | 1.150 | 0.437 | ||||
| IL-18 C/G | N | 156/372 | 51/130 | 3/8 | 0.871 | 83/376 | 29/121 | 3/8 | 0.552 | 239/748 | 80/251 | 6/16 | 0.894 |
| % | 41.9 | 39.2 | 37.5 | 22.1 | 24.0 | 37.5 | 32.0 | 31.9 | 37.5 | ||||
| OR | 1.000 | 0.894 | 0.831 | 1.000 | 1.113 | 2.118 | 1.000 | 0.996 | 1.278 | ||||
| IL-18 G/T | N | 54/124 | 100/258 | 56/128 | 0.533 | 32/133 | 54/252 | 29/120 | 0.772 | 86/257 | 154/510 | 85/248 | 0.448 |
| % | 43.5 | 38.8 | 43.8 | 24.1 | 21.4 | 24.2 | 33.5 | 30.2 | 34.3 | ||||
| OR | 1.000 | 0.820 | 1.008 | 1.000 | 0.861 | 1.006 | 1.000 | 0.860 | 1.037 | ||||
| Implantation | |||||||||||||
| IL-1α | N | 254/1070 | 40/151 | 3/5 | 0.122 | 133/1142 | 18/161 | 0/2 | 1.000 | 387/2212 | 58/312 | 3/7 | 0.195 |
| % | 23.7 | 26.5 | 60.0 | 11.6 | 11.2 | 0.0 | 17.5 | 18.6 | 42.9 | ||||
| OR | 1.000 | 1.158 | 4.819 | 1.000 | 0.955 | 0.000 | 1.000 | 1.077 | 3.537 | ||||
| IL-3 | N | 78/285 | 131/600 | 88/341 | 0.145 | 42/360 | 81/702 | 28/243 | 0.998 | 120/645 | 212/1302 | 116/584 | 0.133 |
| % | 27.4 | 21.8 | 25.8 | 11.7 | 11.5 | 11.5 | 18.6 | 16.3 | 19.9 | ||||
| OR | 1.000 | 0.741 | 0.923 | 1.000 | 0.988 | 0.986 | 1.000 | 0.851 | 1.084 | ||||
| IL-15 | N | 216/900 | 81/321 | 0/5 | 0.406 | 107/930 | 41/346 | 3/29 | 0.964 | 323/1830 | 122/667 | 3/34 | 0.368 |
| % | 24.0 | 25.2 | 0.0 | 11.5 | 11.8 | 10.3 | 17.7 | 18.3 | 8.8 | ||||
| OR | 1.000 | 1.069 | 0.000 | 1.000 | 1.034 | 0.887 | 1.000 | 1.044 | 0.452 | ||||
| IL-18 C/G | N | 219/896 | 75/311 | 3/19 | 0.683 | 108/982 | 39/302 | 4/21 | 0.369 | 327/1878 | 114/613 | 7/40 | 0.800 |
| % | 24.4 | 24.1 | 15.8 | 11.0 | 12.9 | 19.0 | 17.4 | 18.6 | 17.5 | ||||
| OR | 1.000 | 0.982 | 0.580 | 1.000 | 1.200 | 1.904 | 1.000 | 1.084 | 1.006 | ||||
| IL-18 G/T | N | 69/296 | 147/615 | 81/315 | 0.759 | 39/345 | 75/640 | 37/320 | 0.981 | 108/641 | 222/1255 | 118/635 | 0.719 |
| % | 23.3 | 23.9 | 25.7 | 11.3 | 11.7 | 11.6 | 16.8 | 17.7 | 18.6 | ||||
| OR | 1.000 | 1.033 | 1.139 | 1.000 | 1.042 | 1.026 | 1.000 | 1.061 | 1.126 | ||||
| Abortion | |||||||||||||
| IL-1α | N | 13/180 | 1/28 | 0/2 | 0.737 | 16/100 | 3/15 | 0.712 | 29/280 | 4/43 | 0/2 | 1.000 | |
| % | 7.2 | 3.6 | 0.0 | 16.0 | 20.0 | 10.4 | 9.3 | 0.0 | |||||
| OR | 1.000 | 0.476 | 0.000 | 1.000 | 1.313 | 1.000 | 0.888 | 0.000 | |||||
| IL-3 | N | 7/55 | 5/94 | 2/61 | 0.121 | 7/30 | 6/61 | 6/24 | 0.110 | 14/85 | 11/155 | 8/85 | 0.069 |
| % | 12.7 | 5.3 | 3.3 | 23.3 | 9.8 | 25.0 | 16.5 | 7.1 | 9.4 | ||||
| OR | 1.000 | 0.385 | 0.232 | 1.000 | 0.358 | 1.095 | 1.000 | 0.387 | 0.527 | ||||
| IL-15 | N | 8/154 | 6/56 | 0.208 | 13/78 | 6/35 | 0/2 | 1.000 | 21/232 | 12/91 | 0/2 | 0.441 | |
| % | 5.2 | 10.7 | 16.7 | 17.1 | 0.0 | 9.1 | 13.2 | 0.0 | |||||
| OR | 1.000 | 2.190 | 1.000 | 1.034 | 0.000 | 1.000 | 1.526 | 0.000 | |||||
| IL-18 C/G | N | 12/156 | 2/51 | 0/3 | 0.614 | 14/83 | 5/29 | 0/3 | 1.000 | 26/239 | 7/80 | 0/6 | 0.610 |
| % | 7.7 | 3.9 | 0.0 | 16.9 | 17.2 | 0.0 | 10.9 | 8.8 | 0.0 | ||||
| OR | 1.000 | 0.490 | 0.000 | 1.000 | 1.027 | 0.000 | 1.000 | 0.786 | 0.000 | ||||
| IL-18 G/T | N | 5/54 | 6/100 | 3/56 | 0.721 | 5/32 | 9/54 | 5/29 | 0.985 | 10/86 | 15/154 | 8/85 | 0.867 |
| % | 9.3 | 6.0 | 5.4 | 15.6 | 16.7 | 17.2 | 11.6 | 9.7 | 9.4 | ||||
| OR | 1.000 | 0.626 | 0.555 | 1.000 | 1.080 | 1.125 | 1.000 | 0.820 | 0.790 | ||||
| Live birth | |||||||||||||
| IL-1α | N | 159/444 | 27/64 | 2/2 | 0.098 | 73/440 | 9/64 | 0/1 | 0.764 | 232/884 | 36/128 | 2/3 | 0.234 |
| % | 35.8 | 42.2 | 100.0 | 16.6 | 14.1 | 0.0 | 26.2 | 28.1 | 66.7 | ||||
| OR | 1.000 | 1.308 | - | 1.000 | 0.823 | 0.000 | 1.000 | 1.100 | 5.621 | ||||
| IL-3 | N | 45/117 | 85/250 | 58/143 | 0.397 | 19/136 | 46/269 | 17/100 | 0.703 | 64/253 | 131/519 | 75/243 | 0.226 |
| % | 38.5 | 34.0 | 40.6 | 14.0 | 17.1 | 17.0 | 25.3 | 25.2 | 30.9 | ||||
| OR | 1.000 | 0.824 | 1.092 | 1.000 | 1.270 | 1.261 | 1.000 | 0.997 | 1.318 | ||||
| IL-15 | N | 138/378 | 50/130 | 0/2 | 0.650 | 58/361 | 22/134 | 2/10 | 0.944 | 196/739 | 72/264 | 2/12 | 0.715 |
| % | 36.5 | 38.5 | 0.0 | 16.1 | 16.4 | 20.0 | 26.5 | 27.3 | 16.7 | ||||
| OR | 1.000 | 1.087 | 0.000 | 1.000 | 1.026 | 1.306 | 1.000 | 1.039 | 0.554 | ||||
| IL-18 C/G | N | 140/372 | 45/130 | 3/8 | 0.828 | 60/376 | 20/121 | 2/8 | 0.786 | 200/748 | 65/251 | 5/16 | 0.883 |
| % | 37.6 | 34.6 | 37.5 | 16.0 | 16.5 | 25.0 | 26.7 | 25.9 | 31.3 | ||||
| OR | 1.000 | 0.877 | 0.994 | 1.000 | 1.043 | 1.756 | 1.000 | 0.958 | 1.245 | ||||
| IL-18 G/T | N | 46/124 | 92/258 | 50/128 | 0.807 | 19/133 | 40/252 | 23/120 | 0.562 | 65/257 | 132/510 | 73/248 | 0.501 |
| % | 37.1 | 35.7 | 39.1 | 14.3 | 15.9 | 19.2 | 25.3 | 25.9 | 29.4 | ||||
| OR | 1.000 | 0.940 | 1.087 | 1.000 | 1.132 | 1.423 | 1.000 | 1.032 | 1.232 | ||||
AA: homozygous major, Aa: heterozygous, aa: homozygous minor, OR: Odds ratio. p-Value by Chi-square test or Fisher’s exact test when appropriated.
Table 4.
Effect of Interleukin polymorphisms on IVF outcome (recessive model).
| Variable | Age≤35 | Age>35 | Overall | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AA | Aa/aa | p-Value | AA | Aa/aa | p-Value | AA | Aa/aa | p-Value | ||
| Clinical pregnancy | ||||||||||
| IL-1α | N | 180/444 | 30/66 | 0.449 | 100/440 | 15/65 | 0.950 | 280/884 | 45/131 | 0.540 |
| % | 40.5 | 45.5 | 22.7 | 23.1 | 31.7 | 34.4 | ||||
| OR | 1.000 | 1.222 | 1.000 | 1.020 | 1.000 | 1.129 | ||||
| IL-3 | N | 55/117 | 155/393 | 0.144 | 30/136 | 85/369 | 0.816 | 85/253 | 240/762 | 0.535 |
| % | 47.0 | 39.4 | 22.1 | 23.0 | 33.6 | 31.5 | ||||
| OR | 1.000 | 0.734 | 1.000 | 1.058 | 1.000 | 0.909 | ||||
| IL-15 | N | 154/378 | 56/132 | 0.735 | 78/361 | 37/144 | 0.323 | 232/739 | 93/276 | 0.484 |
| % | 40.7 | 42.4 | 21.6 | 25.7 | 31.4 | 33.7 | ||||
| OR | 1.000 | 1.072 | 1.000 | 1.255 | 1.000 | 1.111 | ||||
| IL-18 C/G | N | 156/372 | 54/138 | 0.567 | 83/376 | 32/129 | 0.523 | 239/748 | 86/267 | 0.938 |
| % | 41.9 | 39.1 | 22.1 | 24.8 | 32.0 | 32.2 | ||||
| OR | 1.000 | 0.890 | 1.000 | 1.165 | 1.000 | 1.012 | ||||
| IL-18 G/T | N | 54/124 | 156/386 | 0.537 | 32/133 | 83/372 | 0.680 | 86/257 | 239/758 | 0.566 |
| % | 43.5 | 40.4 | 24.1 | 22.3 | 33.5 | 31.5 | ||||
| OR | 1.000 | 0.879 | 1.000 | 0.906 | 1.000 | 0.916 | ||||
| Implantation | ||||||||||
| IL-1α | N | 254/1070 | 43/156 | 0.297 | 133/1142 | 18/163 | 0.822 | 387/2212 | 61/319 | 0.477 |
| % | 23.7 | 27.6 | 11.6 | 11.0 | 17.5 | 19.1 | ||||
| OR | 1.000 | 1.222 | 1.000 | 0.942 | 1.000 | 1.115 | ||||
| IL-3 | N | 78/285 | 219/941 | 0.157 | 42/360 | 109/945 | 0.947 | 120/645 | 328/1886 | 0.486 |
| % | 27.4 | 23.3 | 11.7 | 11.5 | 18.6 | 17.4 | ||||
| OR | 1.000 | 0.805 | 1.000 | 0.987 | 1.000 | 0.921 | ||||
| IL-15 | N | 216/900 | 81/326 | 0.760 | 107/930 | 44/375 | 0.907 | 323/1830 | 125/701 | 0.915 |
| % | 24.0 | 24.8 | 11.5 | 11.7 | 17.7 | 17.8 | ||||
| OR | 1.000 | 1.047 | 1.000 | 1.022 | 1.000 | 1.013 | ||||
| IL-18 C/G | N | 219/896 | 78/330 | 0.770 | 108/982 | 43/323 | 0.259 | 327/1878 | 121/653 | 0.519 |
| % | 24.4 | 23.6 | 11.0 | 13.3 | 17.4 | 18.5 | ||||
| OR | 1.000 | 0.957 | 1.000 | 1.243 | 1.000 | 1.079 | ||||
| IL-18 G/T | N | 69/296 | 228/930 | 0.673 | 39/345 | 112/960 | 0.857 | 108/641 | 340/1890 | 0.513 |
| % | 23.3 | 24.5 | 11.3 | 11.7 | 16.8 | 18.0 | ||||
| OR | 1.000 | 1.068 | 1.000 | 1.036 | 1.000 | 1.083 | ||||
| Abortion | ||||||||||
| IL-1α | N | 13/180 | 1/30 | 0.698 | 16/100 | 3/15 | 0.712 | 29/280 | 4/45 | 1.000 |
| % | 7.2% | 3.3% | 16.0% | 20.0% | 10.4% | 8.9% | ||||
| OR | 1.000 | 0.443 | 1.000 | 1.313 | 1.000 | 0.844 | ||||
| IL-3 | N | 7/55 | 7/155 | 0.055 | 7/30 | 12/85 | 0.261 | 14/85 | 19/240 | 0.025 |
| % | 12.7 | 4.5 | 23.3 | 14.1 | 16.5 | 7.9 | ||||
| OR | 1.000 | 0.324 | 1.000 | 0.540 | 1.000 | 0.436 | ||||
| IL-15 | N | 8/154 | 6/56 | 0.208 | 13/78 | 6/37 | 0.952 | 21/232 | 12/93 | 0.299 |
| % | 5.2 | 10.7 | 16.7 | 16.2 | 9.1 | 12.9 | ||||
| OR | 1.000 | 2.190 | 1.000 | 0.968 | 1.000 | 1.489 | ||||
| IL-18 C/G | N | 12/156 | 2/54 | 0.527 | 14/83 | 5/32 | 0.872 | 26/239 | 7/86 | 0.471 |
| % | 7.7 | 3.7 | 16.9 | 15.6 | 10.9 | 8.1 | ||||
| OR | 1.000 | 0.462 | 1.000 | 0.913 | 1.000 | 0.726 | ||||
| IL-18 G/T | N | 5/54 | 9/156 | 0.358 | 5/32 | 14/83 | 0.872 | 10/86 | 23/239 | 0.598 |
| % | 9.3 | 5.8 | 15.6 | 16.9 | 11.6 | 9.6 | ||||
| OR | 1.000 | 0.600 | 1.000 | 1.096 | 1.000 | 0.809 | ||||
| Live birth | ||||||||||
| IL-1α | N | 159/444 | 29/66 | 0.202 | 73/440 | 9/65 | 0.575 | 232/884 | 38/131 | 0.504 |
| % | 35.8 | 43.9 | 16.6 | 13.8 | 26.2 | 29.0 | ||||
| OR | 1.000 | 1.405 | 1.000 | 0.808 | 1.000 | 1.148 | ||||
| IL-3 | N | 45/117 | 143/393 | 0.683 | 19/136 | 63/369 | 0.402 | 64/253 | 206/762 | 0.588 |
| % | 38.5 | 36.4 | 14.0 | 17.1 | 25.3 | 27.0 | ||||
| OR | 1.000 | 0.915 | 1.000 | 1.268 | 1.000 | 1.094 | ||||
| IL-15 | N | 138/378 | 50/132 | 0.779 | 58/361 | 24/144 | 0.869 | 196/739 | 74/276 | 0.926 |
| % | 36.5 | 37.9 | 16.1 | 16.7 | 26.5 | 26.8 | ||||
| OR | 1.000 | 1.060 | 1.000 | 1.045 | 1.000 | 1.015 | ||||
| IL-18 C/G | N | 140/372 | 48/138 | 0.553 | 60/376 | 22/129 | 0.771 | 200/748 | 70/267 | 0.869 |
| % | 37.6 | 34.8 | 16.0 | 17.1 | 26.7 | 26.2 | ||||
| OR | 1.000 | 0.884 | 1.000 | 1.083 | 1.000 | 0.974 | ||||
| IL-18 G/T | N | 46/124 | 142/386 | 0.950 | 19/133 | 63/372 | 0.477 | 65/257 | 205/758 | 0.583 |
| % | 37.1 | 36.8 | 14.3 | 16.9 | 25.3 | 27.0 | ||||
| OR | 1.000 | 0.987 | 1.000 | 1.223 | 1.000 | 1.095 | ||||
AA: homozygous major, Aa: heterozygous, aa: homozygous minor, OR: Odds ratio. p-Value by Chi-square test or Fisher’s exact test when appropriated.
Table 5.
Baseline characteristics and IVF treatment cycle parameters of IL-3 polymorphisms patients.
Table 5.
Baseline characteristics and IVF treatment cycle parameters of IL-3 polymorphisms patients.
| Variable | IL-3 | ||
|---|---|---|---|
| CC (n = 253) | CT/TT (n = 762) | p-Value | |
| Age (years) | 35.81 ± 4.82 | 35.46 ± 4.48 | 0.308 |
| Duration of infertility (years) | 3.54 ± 2.84 | 3.72 ± 3.20 | 0.415 |
| Total gonadotropin doses (IU) | 2350.32 ± 1512.96 | 2283.76 ± 1405.19 | 0.622 |
| Basal FSH (mIU/mL) | 7.28 ± 5.04 | 6.94 ± 3.86 | 0.266 |
| Basal LH (mIU/mL) | 5.63 ± 4.59 | 5.75 ± 5.78 | 0.760 |
| Basal AMH (mIU/mL) | 3.11 ± 2.89 | 3.15 ± 2.92 | 0.834 |
| Basal oestradiol (pg/mL) | 36.48 ± 24.43 | 37.15 ± 25.14 | 0.711 |
| Peak estradiol (pg/mL) * | 1835.5 ± 1310.89 | 1910.04 ± 1351.89 | 0.509 |
| P4 ng/ml at HCG injection day | 2.01 ± 12.73 | 1.55 ± 6.79 | 0.526 |
| No. of oocytes retrieved | 9.52 ± 6.31 | 10.20 ± 6.73 | 0.162 |
| Mature oocytes | 7.54 ± 5.56 | 8.33 ± 6.36 | 0.080 |
| Fertilization rate (%) | 81.59 ± 22.41 | 82.99 ± 20.58 | 0.481 |
| Day3 embryo no. | 7.82 ± 5.41 | 7.57 ± 5.16 | 0.641 |
| Day3 good embryo rate (%) | 59.56 ± 22.67 | 61.63 ± 23.38 | 0.393 |
| Day5 good embryo rate (%) | 45.93 ± 21.24 | 47.11 ± 22.78 | 0.734 |
| No. of transferred embryos | 2.55 ± 0.90 | 2.48 ± 0.85 | 0.256 |
| Endometrial thickness (mm) ** | 11.83 ± 1.86 | 11.78 ± 2.24 | 0.819 |
| Clinical pregnancy (%) | 85/253 (33.6%) | 240/762 (31.5%) | 0.535 |
| Implantation (%) | 120/645 (18.6%) | 328/1886 (17.4%) | 0.486 |
| Abortion (%) | 14/85 (16.5%) | 19/240 (7.9%) | 0.025 |
| Abortion per cycle (%) | 14/253 (5.5%) | 19/762 (2.5%) | 0.018 |
| Live birth (%) | 64/253 (25.3%) | 206/762 (27.0%) | 0.588 |
| Aetiology of infertility | |||
| Male factor (%) | 53 (21.0) | 174 (22.8) | 0.286 |
| Tubal factor (%) | 44 (17.4) | 137 (18.0) | 0.507 |
| Endometriosis (%) | 15 (5.9) | 47 (6.2) | 1.000 |
| PCOS (%) | 25 (9.9) | 81 (10.6) | 0.745 |
| Unexplained (%) | 14 (5.5) | 67 (8.8) | 0.313 |
| Advance maternal age (%) | 78 (30.8) | 197 (25.9) | 0.744 |
| Multiple factors (%) | 24 (9.5) | 59 (7.7) | 1.000 |
CC: homozygous major, CT: heterozygous, TT: homozygous minor. Values presented as mean ± standard deviation; p-Value by Student’s t-test. * levels on the trigger day, ** thickness on the day of embryo transfer.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Wu, C.-H.; Lee, T.-H.; Yang, S.-F.; Tsao, H.-M.; Chang, Y.-J.; Chou, C.-H.; Lee, M.-S. Interleukin-3 Polymorphism is Associated with Miscarriage of Fresh in Vitro Fertilization Cycles. Int. J. Environ. Res. Public Health 2019, 16, 995. https://doi.org/10.3390/ijerph16060995
AMA Style
Wu C-H, Lee T-H, Yang S-F, Tsao H-M, Chang Y-J, Chou C-H, Lee M-S. Interleukin-3 Polymorphism is Associated with Miscarriage of Fresh in Vitro Fertilization Cycles. International Journal of Environmental Research and Public Health. 2019; 16(6):995. https://doi.org/10.3390/ijerph16060995
Chicago/Turabian StyleWu, Cheng-Hsuan, Tsung-Hsien Lee, Shun-Fa Yang, Hui-Mei Tsao, Yu-Jun Chang, Chia-Hsuan Chou, and Maw-Sheng Lee. 2019. "Interleukin-3 Polymorphism is Associated with Miscarriage of Fresh in Vitro Fertilization Cycles" International Journal of Environmental Research and Public Health 16, no. 6: 995. https://doi.org/10.3390/ijerph16060995
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
